NCT05945823 2025-12-29
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
4 trialsNCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04210115 2024-11-15
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting